Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
Thats because glutathione supplements are not always absorbed well by the body
Some compounding operations may face restrictions, which could affect supply chains and potentially lead to pharmacy switches for patients on ongoing treatment programs
Pricing: see our peptide pricing page
Please let me know
